The money will be used for a proposed trial that examines the safety and efficacy of Acer-801, a medication from Acer Therapeutics, in reducing PTSD responses.
Trial sites include Washington University in St. Louis, Amherst-based University of Massachusetts Chan Medical School, University of Florida College of Medicine Jacksonville, and Bloomington-based Indiana University School of Medicine.
The proposed study will begin in the first half of 2023.
“We have been able to provide emergency care to address immediate and long-term problems after visible wounds using tools such as sutures and antibiotics. However, we still have nothing to offer trauma survivors, whether in the emergency department or on the battlefield immediately after trauma, to prevent the development of ‘invisible wounds,'” Dr. McLean said in an Oct. 6 press release from the university. “We need to investigate potential treatments like Acer-801 in an effort to better address these challenges.”
